---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-25-000081"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2025-09-29T23:59:59+00:00"
generated_at: "2026-05-17T05:22:31.235442+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio to split into two public companies by end of 2026; royalty assets separate from biopharma

## Summary
- CEO Daniel Faga expected to lead Biopharma Co; Royalty Co holds Jemperli (GSK) and imsidolimab (Vanda) royalties.
- Jemperli royalties tiered: 8% up to $1B sales, 12% $1-1.5B, 20% $1.5-2.5B, 25% above $2.5B; GSK peak sales guide >£2B.
- Sagard monetization capped at $600M; expected paydown mid-2027 to Q2 2028.
- Biopharma Co pipeline: rosnilimab (Phase 2b RA, Phase 2 UC top-line Nov/Dec 2025), ANB033 (celiac Ph1b), ANB101 (Ph1a).
- Separation targeted by year-end 2026; taxable but minimizing taxes; subject to board and SEC approval.

## SEC filing metadata
- accession: 0001370053-25-000081
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2025-09-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005325000081/0001370053-25-000081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005325000081/anab-20250929.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-25-000081
- JSON: https://secwatch.observer/filing/0001370053-25-000081.json
- Plain text: https://secwatch.observer/filing/0001370053-25-000081.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.